the next generation biopharma leader · 2016-01-20 · the next generation biopharma leader may...
TRANSCRIPT
Raffaele, living with epilepsy
May 2009
Delivering to becomethe next generation biopharma leader
UCB
Corporate Presentation
the n
ext generation
bioph
arma lead
erM
ay 2009
2
Disclaimer and safe harbour
Forward-looking statements:
This presentation includes “forward-looking statements” relating to UCB and Schwarz Pharma that are subject to known and unknown risks and uncertainties, many of which are outside of UCB’s and Schwarz Pharma’s control and are difficult to predict, that may cause actual results to differ materially from any future results expressed or implied from the forward-looking statements. In this presentation, the words “anticipates,”“believes,” “estimates,” “seeks,” “expects,” “plans,” “intends” and similar expressions, as they relate to UCB or Schwarz Pharma, are intended to identify forward-looking statements. Important factors that could cause actual results to differ materially from such expectations include, without limitation: the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms; the inability to integrate successfully Schwarz Pharma within UCB or to realize synergies from such integration following the acquisition; costs related to the acquisition of Schwarz Pharma; the economic environment of the industries in which UCB and Schwarz Pharma operate; costs associated with research and development; changes in the prospects for products in the pipeline or under development by UCB or Schwarz Pharma; dependence on the existing management of UCB and Schwarz Pharma; changes or uncertainties in Belgian or German tax laws or the administration of such laws; changes or uncertainties in the laws or regulations applicable to the markets in which UCB and Schwarz Pharma operate. All written and oral forward-looking statements attributable to UCB or Schwarz Pharma or persons acting on either of their behalf are expressly qualified in their entirety by the cautionary statements above. Neither UCB nor Schwarz Pharma intend, or undertake any obligation, to update these forward-looking statements.
the n
ext generation
bioph
arma lead
erM
ay 2009
3
UCB
Vision
• To become the next generation biopharmaceutical leader
• To provide breakthrough innovation for patients suffering from severe diseases
Therapeutic focus
• Central nervous system (CNS)
• Immunology
Foundation
• UCB = UCB Pharma + Celltech (2004) + Schwarz Pharma (2006)
• UCB = unique combination of large, antibody-based molecules and small, chemically-derived molecules
the n
ext generation
bioph
arma lead
erM
ay 2009
4
UCB Our “road map”
2007 ... and beyond
Realise the commercial potential of new products
Launch a new generation of therapies offering breakthrough innovation to patients with severe disease
Intense growth
Breakthrough
• Launch new products• Invest in R&D• SHAPE the organisation for the future
• Prioritise products and markets• Improve competitiveness and profitability
Execution
2010
the n
ext generation
bioph
arma lead
erM
ay 2009
5
2008UCB continues on track
SHAPE: major steps taken to accelerate the transformation of the
organisation and to increase focus on UCB core disease areas,
products and geographies
2008: three new molecular entities (NME’s) approved in the U.S.
2008/2009: major product launches - Vimpat®, Neupro®,
Cimzia® - ongoing and in preparation
In-line with financial guidance
the n
ext generation
bioph
arma lead
erM
ay 2009
6
2008 Financial highlights
Revenue of € 3 601 million in line with previous year
Recurring EBITDA of € 733 million (-1%)
Net profit € 42 million (-74%) impacted by:
• Significant restructuring expenses and fixed asset impairment charges related to the SHAPE programme
• Financial expenses related to purchase of minority Schwarz Pharma shares
Adjusted1 net profit € 270 million (-7%)
1 Adjusted for after-tax impact of one-off items, contribution from discontinued operations and inventory step-up
the n
ext generation
bioph
arma lead
erM
ay 2009
7
Seven regulatory approvals• Cimzia® Crohn's disease (U.S.) - launched
• Keppra® XR Adjunctive therapy in epilepsy (U.S.) - launched
• Neupro® Restless legs syndrome (EU) – launch expected H1 2009
• Toviaz® Overactive bladder (U.S.) – licensed to Pfizer
• Vimpat® Adjunctive therapy in epilepsy (EU) - launched
• Vimpat® Adjunctive therapy in epilepsy (U.S.) - launch expected Q2 2009
• Xyzal® Antihistamine oral solution (U.S.) - launched
Six filings• Cimzia® Rheumatoid arthritis (EU)
• Cimzia® Rheumatoid arthritis (U.S.)
• Keppra® Adjunctive therapy in epilepsy (infants and children1 – U.S.)
• Keppra® Adjunctive therapy in epilepsy (infants and children1 – EU)
• Keppra® Adjunctive therapy in epilepsy (Japan)
• Keppra® XR Adjunctive therapy in epilepsy (U.S.)
1 For children aged from one month to under four years
2008 7 regulatory approvals and 6 filings
the n
ext generation
bioph
arma lead
erM
ay 2009
8
3
2008Most NME approvals in the U.S.
Three out of 24 NME1 approvals in 2008 for UCB
and one out of four Biologics License Applications (BLA) approved
0
1
2
3
ADO
LOR
AMG
EN
ASTE
LLAS
BAYE
R H
LTHC
ARE
BIO
VAIL
AM
ERIC
ASC
EPHA
LON
EISA
IEP
IX P
HAR
MA
FER
RIN
GG
E HE
ALTH
CAR
E
GEN
ZYM
EG
LAXO
SMIT
HKL
INE
MED
S C
OO
RTH
O M
CNEI
L JA
NSS
ENPR
OG
ENIC
S R
EGEN
ERO
N PH
ARM
.SI
RIO
N TH
ERAP
TIBO
TEC
UCB
3W
ATSO
N L
ABS
WYE
TH P
HAR
MS
INC
1 New Molecular Entity - Source: FDA website2 Adolor and GlaxoSmithKline collaborated on Entereg3 Progenics and Wyeth collaborated on Relistor4 Toviaz® (Pfizer), Vimpat® (Schwarz Pharma) and Cimzia® are all
grouped under UCB - Toviaz® is officially listed on FDA site as Pfizer. NDA filed by Schwarz Pharma and while approvable, was transferred to Pfizer
UCB42
the n
ext generation
bioph
arma lead
erM
ay 2009
9
20084 + 1 new product launches
Crohn's disease
Launched in the U.S.
Adjunctive therapy in epilepsy
Launched in Germany and U.K.
Adjunctive therapy in epilepsy
Launched in the U.S.
Oral antihistamine solution
Launched in the U.S.
Overactive bladder
Launched in the EU, by PfizerToviaz®
the n
ext generation
bioph
arma lead
erM
ay 2009
10
Solid CNS & immunology pipelineKey projects
Neupro®
restless legs syndrome – EU
Neupro®
restless legs syndrome - U.S.1
Vimpat®
diabetic neuropathic pain - EU + U.S.
epratuzumabsystemic lupus erythematosus
CDP6038autoimmune diseases
Immunology
Cimzia®
rheumatoid arthritis - EU + U.S.2
Neupro®
adv. Parkinson's disease - U.S1
Filed
CNS
Cimzia®
Crohn's disease -EU
Keppra® XRepilepsy monotherapy - U.S.
brivaracetamepilepsy
Vimpat®
epilepsy adjunctive therapy – U.S.
Vimpat®
epilepsy monotherapy - U.S.
CDP323multiple sclerosis
CDP7851bone loss disorders
Approved Phase IIIPhase IIPhase I
1 Neupro® Complete Response Letter (December 2008)2 Cimzia® Complete Response Letter (January 2009)
the n
ext generation
bioph
arma lead
erM
ay 2009
11
CNS Expansion in our core area
Epilepsy Vimpat®
brivaracetam
Parkinson's disease (PD) Neupro®
Restless legs syndrome (RLS) Neupro®
Diabetic neuropathic pain (DNP) Vimpat®
Multiple sclerosis (MS) CDP323
the n
ext generation
bioph
arma lead
erM
ay 2009
12
EpilepsyMajor unmet medical need
High unmet medical need in ~1/3 of treated epilepsy patients
Patients with only one seizure/month report significant impact on their social life, ability to work and standard of living
No new AED’s1 approved in over five years (U.S.)
Few future treatments expected, particularly with a novel mode of action
There is a strong need for a new treatment option
Controlled on 1st Monotherapy
Uncontrolled despite 2-3 AEDs
"Controlled" on more than 1 AED20-25%
50% 25-30%
1 Antiepileptic drug
the n
ext generation
bioph
arma lead
erM
ay 2009
13
Brivaracetam in epilepsyPhase III programme ongoing
Broader mechanism of action than Keppra®
Population includes patients not controlled with Keppra®
Phase III top line results (April 2009):
• Study N01253 met its primary efficacy endpoint
• Study N01252 did not meet its primary efficacy endpoint
• Study N01254 confirmed brivaracetam was well tolerated
• Further analysis will be conducted
• Regulatory authorities will be consulted to determine next steps
Path forward update expected by year end
LaunchedApprovedFiledPhase IIIPhase IIPhase I
April 2009Epilepsy adjunctive therapyBrivaracetam
the n
ext generation
bioph
arma lead
erM
ay 2009
14
Neupro® in Parkinson's diseaseWorking to make it available for new patients
Full cold storage and distribution chain
implemented in Europe (September 2008)
• Target: to make Neupro® available again to all patients
(including new patients) in Europe during H1 2009
To resolve U.S. out-of-stock situation
• FDA Complete Response Letter (December 2008)
• “Substantial evidence of effectiveness in advanced
Parkinson’s disease and restless legs syndrome (RLS)”
• Dialogue ongoing with the FDA
January2007Advanced Parkinson's disease (EU)Neupro® (rotigotine)
July2007Early stage Parkinson's disease (U.S.)Neupro® (rotigotine)
LaunchedApprovedFiledPhase IIIPhase IIPhase I
December 2007Advanced Parkinson's disease (U.S.)Neupro® (rotigotine)
March 2006Early stage Parkinson's disease (EU)Neupro® (rotigotine)
Add
New
patien
t fr
om A
R
Terry, living with Parkinson’s disease
the n
ext generation
bioph
arma lead
erM
ay 2009
15
Neupro® in restless legs syndrome Increased awareness of an unrecognised disease
Demonstrated efficacy
Well tolerated
Consistent results within comprehensive clinical
program
• Improved sleep and reduced daytime tiredness
• Potential first line treatment EU approval (September
2008)
FDA Complete Response Letter (December 2008)
• “Substantial evidence of effectiveness in advanced
Parkinson’s disease and restless legs syndrome (RLS)”
LaunchedApprovedFiledPhase IIIPhase IIPhase I
December2007Restless legs syndrome (U.S.)Neupro® (rotigotine)
September 2008Restless legs syndrome (EU)Neupro® (rotigotine)
Sten, living with restless legs syndrome
the n
ext generation
bioph
arma lead
erM
ay 2009
16
Vimpat® in diabetic neuropathic painPath forward to be elaborated
Promising drug for a large unmet medical need
• Demonstrated sustained efficacy and good tolerability
• No drug-drug / food interactions, no weight gain
• New mode of action
FDA Not Approvable Letter (July 2008)
Withdrawal of MAA1 in EU (September 2008)
• Optimise design of future studies to meet conservative
statistical requirements and then discuss with
authorities
UCB decision expected H2 2009
LaunchedApprovedFiledPhase IIIPhase IIPhase I
Diabetic neuropathic pain (U.S.)Vimpat® (lacosamide)
Vimpat® (lacosamide) Diabetic neuropathic pain (EU)
1 Marketing Authorisation Application
Frieda, living with diabetic neuropathic pain
the n
ext generation
bioph
arma lead
erM
ay 2009
17
CDP323 in multiple sclerosisOral administration
Potent and orally active small molecule antagonist of alpha 4-integrin
Successful collaboration with Biogen IDEC
Phase II programme ongoing
Results expected
2010Multiple sclerosisCDP323
LaunchedApprovedFiledPhase IIIPhase IIPhase I
the n
ext generation
bioph
arma lead
erM
ay 2009
18
Immunology
Crohn's disease (CD) Cimzia®
Rheumatoid arthritis (RA) Cimzia®
Bone loss disorders CDP7851
Systemic lupus erythematosus (SLE) epratuzumab
the n
ext generation
bioph
arma lead
erM
ay 2009
19
Cimzia® in rheumatoid arthritis Only PEGylated Fc-free anti-TNF
FDA Complete Response Letter (January 2009)
Meeting with FDA defined path forward (February 2009)
• No new studies required (clinical or non-clinical)
• Further analysis of existing data and a new safety update
UCB response now submitted
February 2008Rheumatoid arthritis (U.S.)Cimzia® (certolizumab pegol)July 2008Rheumatoid arthritis (EU)Cimzia® (certolizumab pegol)
LaunchedApprovedFiledPhase IIIPhase IIPhase I
Alison, living with rheumatoid arthritis
the n
ext generation
bioph
arma lead
erM
ay 2009
20
CDP7851 in bone loss disorders Novel therapy with strong potential
Development of novel anabolic therapy
• Antibody to sclerostin potentially treating bone loss
disorders, incl. osteoporosis
Collaborative project with Amgen
Phase I: first positive results
• UCB and Amgen are encouraged by the first-in-
human data and are currently planning the future
development program Normal Sclerosteosis
Study of naturally occurring human disorder leads to a potential new drug therapy
Results expected H2
2009Bone loss disordersCDP7851 (anti-sclerostin)
LaunchedApprovedFiledPhase IIIPhase IIPhase I
the n
ext generation
bioph
arma lead
erM
ay 2009
21
Epratuzumab in systemic lupus erythematosus (SLE)Phase IIb study has started
Analyses of recently closed clinical trials suggest a favorable efficacy
and tolerability profile
A Phase IIb dose ranging study has started
• Number of randomized patients: 210
• Arms/doses: 6 arms dose range (from 150–3600 mg/cycle)
• Duration: 3 months treatment phase
• Primary endpoint: reduction disease activity
• Population: patients with moderate/severe activity
Results expected Q3 2009
Systemic lupus erythematosusEpratuzumab
LaunchedApprovedFiledPhase IIIPhase IIPhase I
the n
ext generation
bioph
arma lead
erM
ay 2009
22
Solid CNS & immunology pipelineKey projects
Neupro®
restless legs syndrome – EU
Neupro®
restless legs syndrome - U.S.1
Vimpat®
diabetic neuropathic pain -EU + U.S.
epratuzumabsystemic lupus erythematosus
CDP6038autoimmune diseases
Immunology
Cimzia®
rheumatoid arthritis - EU + U.S.2
Neupro®
adv. Parkinson's disease - U.S1
Filed
CNS
Cimzia®
Crohn's disease -EU
Keppra® XRepilepsy monotherapy - U.S.
brivaracetamepilepsy
Vimpat®
epilepsy adjunctive therapy – U.S.
Vimpat®
epilepsy monotherapy - U.S.
CDP323multiple sclerosis
CDP7851bone loss disorders
Approved Phase IIIPhase IIPhase I
1 Neupro® Complete Response Letter (December 2008)2 Cimzia® Complete Response Letter (January 2009)
the n
ext generation
bioph
arma lead
erM
ay 2009
23
SHAPE Transformation and focus
Focus on CNS and immunology
Focus on core products and geographies
Drive for breakthrough innovation for patients with severe disease
Simplify the organisation
Improve competitiveness and profitability
the n
ext generation
bioph
arma lead
erM
ay 2009
24
SHAPEAchievements so far
Organisation simplified and focused• Workforce already reduced by 15%
Resources reallocated to core assets
Pre-clinical oncology portfolio incubated with Wilex (January 2009)• UCB retains buy-back options
Non-strategic emerging markets divested to GSK (January 2009)
Equasym™ IR/XL and Somatostatine-UCB™ divested (February 2009)
UCB NewMedicines™• Drug discovery to proof-of-concept organisation
• New external focus reinforced through new partnerships with academic collaborations
• CDP6038 (IL-6) for auto-immune diseases entered Phase I (December 2008)
the n
ext generation
bioph
arma lead
erM
ay 2009
25
Major development milestones in 2009
Epratuzumab in SLE First Phase IIb results Q3 2009
Brivaracetam in epilepsy Phase III top line results
CDP7851 in bone loss disorders Phase I to complete H2 2009
the n
ext generation
bioph
arma lead
erM
ay 2009
26
UCB priorities for 2009
Successfully launch Vimpat®, Neupro®, Cimzia®
Continue delivery of late stage pipeline
SHAPE:
• Maximise core assets, optimise non-core assets
• Fully implement new organisational and geographical footprint
Prepare for ‘Breakthrough Phase’ by building pipeline and strengthening new biopharma capabilities
Foster patient centricity as a key driver of performance
the n
ext generation
bioph
arma lead
erM
ay 2009
27
2009 financial outlook
Revenue expected to reach between € 3.1 - 3.3 billion
• Full generic competition to Keppra® in the U.S for the whole year
• Partially compensated by newly launched products
Recurring EBITDA target increased to greater than € 680 million
• Swift implementation of the SHAPE programme
Net Profit expected to exceed € 130 million
• Excluding expected capital gains resulting from already announced
divestments
the n
ext generation
bioph
arma lead
erM
ay 2009
28
UCB Our “road map”
2007 ... and beyond
Realise the commercial potential of new products
Launch a new generation of therapies offering breakthrough innovation to patients with severe disease
Intense growth
Breakthrough
• Launch new products• Invest in R&D• SHAPE the organisation for the future
• Prioritise products and markets• Improve competitiveness and profitability
Execution
2010
the n
ext generation
bioph
arma lead
erM
ay 2009
29
Appendix
the n
ext generation
bioph
arma lead
erM
ay 2009
30
Epilepsy
The most common serious neurological disorder
Excessive electrical activity in part or all of the brain resulting in recurrent seizures
In most cases, there is no known cause for epilepsy
Can affect anyone regardless of age, gender or ethnicity
There is no known cure at this time but treatments are available to reduce the frequency and severity of seizures
Prevalence: ≈ 6 million patients in 7 major markets1
Market size: ≈ € 3.2 billion in 7 major markets2 (2007)
1 PatientBase, Decision Resources - 20082 IMS, 2008 - Sales in epilepsy only. Japan not included. U.S. =
Retail + Non-Fed hospitals
the n
ext generation
bioph
arma lead
erM
ay 2009
31
Parkinson’s disease (PD)
CNS disorder, which is the result of the loss of dopamine-producing brain cells
Primary symptoms are tremor and trembling; stiffness of the limbs and trunk; slowness of movement and impaired balance and coordination
No cure but a variety of medications provide relief from the symptoms
Prevalence: ≈ 3 million patients in 7 major markets1
Market size: ≈ € 790 million in 7 major markets2 (2007)
1 PatientBase, Decision Resources - 20082 Sales in PD only - EU 5 only. Source: IMS, 2008
the n
ext generation
bioph
arma lead
erM
ay 2009
32
Restless legs syndrome (RLS)
Neurological condition that is characterised by the irresistible urge to move the legs
The cause is unknown in most patients, but is suspected to be relatedto lack of dopamine in the brain
It is a lifelong condition for which there is no cure
Few treatments available to treat moderate to severe RLS
Prevalence: ≈ 54 million patients in 7 major markets1
Market size: ≈ € 100 million in 7 major markets2 (2007)
1 PatientBase, Decision Resources - 20082 Sales in RLS only. Source: IMS, EU5, Mat 11/08
the n
ext generation
bioph
arma lead
erM
ay 2009
33
Diabetic neuropathic pain (DNP)
Pain associated with a functional abnormality of the nervous system
Several sub-types of neuropathic pain exist
Symptoms depend on the type of nerves affected and are often associated with damage to the motor nerve such as muscle weakness, cramps, and spasms
Very difficult to treat with only some 40-60% of patients achieving partial relief
Prevalence: ≈ 10 million patients in 7 major markets1
Market size: ≈ € 390 million in 7 major markets2 (2007)
1 PatientBase, Decision Resources - 20082 Decision Resources – Neuropathic Pain – April 2007
the n
ext generation
bioph
arma lead
erM
ay 2009
34
Multiple sclerosis (MS)
Chronic, inflammatory, demyelinating disease that affects the central nervous system (CNS)
Affects the ability of nerve cells in the brain and spinal cord to communicate with each other
Cause not known and affects women more than men
No cure but medicines to slow it down, help control symptoms, prevent new attacks, and prevent disability are available
Prevalence: ≈ 536 000 patients in 7 major markets1
Market size: ≈ € 4.3 billion in 7 major markets2 (2007)
1 PatientBase, Decision Resources – 20082 Decision Resources – Pharmacor: Multiple Sclerosis – June 2008
the n
ext generation
bioph
arma lead
erM
ay 2009
35
Crohn’s disease (CD)
Autoimmune disease that causes chronic inflammation of the GI tract
Also referred to as Inflammatory Bowel Disease (IBD)
The cause is not known
Chronic condition, which means you have for life
The disease tends to fluctuate between periods of remission and relapse
There is no known cure for CD but treatments can help reduce symptoms
Prevalence: ≈ 0.9 million patients in 7 major markets1
Market size: ≈ € 0.9 billion in 7 major markets2
1 PatientBase, Decision Resources – 20082 Datamonitor - Autoimmune Overview Forecast: Crohn’s Disease -
December 2007
the n
ext generation
bioph
arma lead
erM
ay 2009
36
Rheumatoid arthritis (RA)
Autoimmune disease that causes chronic and progressive inflammation of the joints
Debilitating systemic condition
The cause of rheumatoid arthritis is not known
Symptoms come and go, depending on the degree of tissue inflammation
There is no known cure for RA but treatments can reduce joint inflammation and pain, maximize joint function, and prevent joint destruction and deformity
Prevalence: ≈ 5 million patients in 7 major markets1
Market size: ≈ € 5.8 billion in 7 major markets2 (2007)
1 PatientBase, Decision Resources – 20082 Decision Resources – Pharmacor: Rheumatoid Arthritis– June
2008
the n
ext generation
bioph
arma lead
erM
ay 2009
37
Bone loss disorders
Reduction of bone mass (density) or presence of a fragility fracture
High associated morbidity and loss of daily independence caused by disease
Treatments available for osteoporosis but significant need to improve the quality of bone restored
Prevalence: ≈ 64 million patients in 7 major markets1
Market size: ≈ € 5.7 billion in 7 major markets2 (2007)
1 PatientBase, Decision Resources - 2008 – Osteoporosis2 Datamonitor – Commercial Insight :Osteoporosis – June 2007
the n
ext generation
bioph
arma lead
erM
ay 2009
38
Systemic Lupus Erythematosus (SLE)
Autoimmune disease that causes inflammation and damage to various body tissues
The word "systemic" means the disease can affect many parts of the body
The cause is not known (usually first affects people between the ages of 15 and 45 years)
The symptoms may be mild or serious, most common ones include extreme fatigue, painful or swollen joints (arthritis), unexplained fever and skin rashes
There is no known cure for SLE but it can be effectively treated with drugs, and most people with the disease can lead active, healthy lives
Prevalence: ≈ 0.6 million patients in 7 major markets1
Market size: ≈ € 670 million in 7 major markets2 (2007)
1 PatientBase, Decision Resources - 20082 Datamonitor, IMS data taking into account off-label sales: both
minimum and maximum sales - Mar08
the n
ext generation
bioph
arma lead
erM
ay 2009
39
Leading products compensate for Zyrtec® decline
YTD Change2008€ million
--2Vimpat®
16%12%58Neupro®
38%29%147Tussionex™
-5%
-
-8%
3%
-49%
23%
Actual1
-7%93Nootropil®
-2%3 027Total net sales
-10Cimzia®
New products
4%173Xyzal® 3
-50%249Zyrtec® (incl. D/Cirrus®)
30%1 266Keppra®
Leading products
CER2
1 Actual: change from previous year unadjusted for foreign currency impact2 CER: change from previous year adjusted for constant exchange rates3 Excluding Xyzal® U.S. revenue to UCB of € 39 million from profit-sharing with
sanofi-aventis
the n
ext generation
bioph
arma lead
erM
ay 2009
40
2008 net salesGeography
Europe42%
Rest of World12%
North America
46%
Europe47%
Rest of World13%
North America
40%
2007 net sales
€ 3 188 million
2008 net sales
€ 3 027 million
*
the n
ext generation
bioph
arma lead
erM
ay 2009
41
2008 net salesTherapy area
CNS37%
Other42%
Immun-ology and
allergy21%
CNS47%
Other39%
Immun- ology & allergy14%
2007 net sales
€ 3 188 million
2008 net sales
€ 3 027 million
*
the n
ext generation
bioph
arma lead
erM
ay 2009
42
Employees Geography - 2008
*
21%
13%
9%21%
20%
16%
Belgium GermanyU.K. U.S.Rest of EU Emerging Markets
Total number of employees
11 292
the n
ext generation
bioph
arma lead
erM
ay 2009
43
Corporate financial calendar
2009 half-year results 31 July
Interim update (nine months report) 22 October
the n
ext generation
bioph
arma lead
erM
ay 2009
44
Your Investor Relations team
Antje Witte, Vice President Corporate Communications & Investor Relations
• Phone +32 2 559 9414
• E-mail: [email protected]
Richard Simpson, Senior Director Investor Relations
• Phone: +32 2 559 9494
• E-mail: [email protected]
Michael Tuck-Sherman, Investor Relations Manager
• Phone: +32 2 559 9712
• E-mail: [email protected]
Isabelle Ghellynck, Investor Relations Project Manager
• Phone: +32 2 559 9588
• E-mail: [email protected]